

Special Issue

Prevention and Early Detection of Prostate Cancer

Message from the Guest Editors

Prostate cancer has a significant heritable component, with more than half of the risk attributed to genetic factors comprised of a spectrum of rare, highly penetrant pathogenic variants in cancer predisposition genes to common single-nucleotide polymorphisms. Additionally, lifestyle modifications such as diet and weight control, smoking cessation, and exercise are increasingly being shown to play a role in decreasing the risk of developing prostate cancer. Early detection of prostate cancer using PSA (prostate specific antigen) remains a controversial topic, and recent data have made multiparametric MRI (magnetic resonance imaging) the new gold standard for early diagnosis and identifying individuals who can be spared aggressive management. This Special Issue will discuss the current evidence and research questions regarding the prevention and early detection of prostate cancer, including the heritable dimension of prostate cancer and the role of multiparametric MRI, PSA screening, and other emerging serologic biomarkers.

Guest Editors

Dr. Channing Judith Paller

Division of Medical Oncology, Sidney Kimmel Cancer Center, The Johns Hopkins University, Baltimore, MD 21287, USA

Dr. Pedro C. Barata

Section of Hematology and Medical Oncology, Department of Internal Medicine, Tulane Medical School, 1430 Tulane Ave, New Orleans, LA 70112, USA

Deadline for manuscript submissions

closed (1 September 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/70381

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)